Ahmed Hamdy M.D. is CEO at Vincerx Pharma, Inc. (VINC). They have made 5 open-market trades across 1 company since 2010, most recently 2026-03-20.
CIK 0001458506
5 open-market purchases totalling $351K since 2021, never a sale. Across 5 scored buys the stock is down 14.6% at ninety days, and 12.1 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 40% | 40% |
| Avg Move | +5.1% | -7.2% | -14.6% |
| Alpha | +6.2% | -6.8% | -12.1% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VINC | BUY | 2023-08-09 | 2023-08-10 | $0.95 | $21K | -4.2% | -24.0% | -9.4% |
| VINC | BUY | 2022-12-14 | 2022-12-14 | $0.87 | $31K | +23.5% | +24.7% | +11.8% |
| VINC | BUY | 2022-06-23 | 2022-06-27 | $1.41 | $34K | +9.1% | +2.8% | -28.0% |
| VINC | BUY | 2021-12-22 | 2021-12-27 | $10.02 | $65K | -6.3% | -33.8% | -60.0% |
| VINC | BUY | 2021-06-29 | 2021-06-30 | $12.77 | $200K | +3.1% | -5.9% | +12.7% |
| PCYC | SELL · 10b5-1 | 2010-10-05 | 2010-10-07 | $8.20 | $123K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.